Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid

Liver

Volumn 19, Issue 2, 1999, Pages 115-121

  Angulo, Paul ^a   Lindor, Keith D ^a   Therneau, Terry M ^a   Jorgensen, Roberta A ^a   Malinchoc, Michael ^a   Kamath, Patrick S ^a   Dickson, E Rolland ^a  

^a MAYO CLINIC   (United States)

Author keywords

Esophageal varices; Mayo risk score; Primary biliary cirrhosis; Prognosis; Ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; PLACEBO; URSODEOXYCHOLIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLEEDING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; ENDOSCOPY; ESOPHAGUS VARICES; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIMARY BILIARY CIRRHOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

EID: 0033061129     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.1999.tb00020.x     Document Type: Article

References (28)

1. POUPON R E, BALKAU B, ESCHWEGE E, et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548-54.
2. POUPON R E, POUPON R, BALKAU B, et al. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994; 330: 1342-7.
3. LINDOR K D, DICKSON E R, BALDUS W P, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-90.
4. HEATHCOTE E J, CAUCH-DUDEK K, WALKER V, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149-56.
5. COMBES B, CARITHERS R L JR., MADDREY W C, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22: 759-66.
6. LINDOR K D, THERNEAU T M, JORGENSEN R A, et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996; 110: 1515-8.
7. POUPON R E, LINDOR K D, CAUCH-DUDEK K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-90.
8. ANGULO P. BATTS K P, THERNEAU T M, et al. Long-term ursodeoxycholic acid delays histologic progression in primary biliary cirrhosis. Hepatology (in press).
9. LINDOR K D, JORGENSEN R A, THERNEAU T M, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997; 72: 1137-40.
10. GORES G J, WIESNER R E, DICKSON E R, et al. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history and influence on survival. Gastroenterology 1989; 96: 1552-9.
11. LEBREC D. Pharmacological prevention of variceal bleeding. In: BOSCH J & GROSZMANN R J eds. Portal hypertension: pathophysiology and treatment. Oxford: Blackwell Scientific Publications, 1994: 72-92.
12. TERAN J C, IMPERIALE T F, MULLEN K D, et al. Primary prophylaxis of variceal bleeding in cirrhosis: a cost-effective analysis. Gastroenterology 1997; 112: 473-82.
13. DICKSON E R, GRAMBSCH P M, FLEMING T R, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10: 1-7.
14. GRAMBSCH P M, DICKSON E R, KAPLAN M, et al. Extramural cross-validation of the mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology 1989; 10: 846-50.
15. KLION F M, FABRY T L, PALMER M, et al. Prediction of survival of patients with primary biliary cirrhosis. Examination of the Mayo Clinic model on a group of patients with known endpoint. Gastroenterology 1992; 102: 310-3.
16. CHRISTENSEN E, ALTMAN D G, NEUBERGER J, et al. Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. Gastroenterology 1993; 105: 1865-76.
17. MARKUS B H, DICKSON E R, GRAMBSCH P M, et al. Efficacy of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989; 320: 1709-13.
18. EMOND M, CARITHERS R L JR., LUKETI V A, et al. Does ursodeoxycholic acid improve survival in patients with primary biliary cirrhosis? Comparison of outcome in the U.S. multicenter trial to expected survival using the Mayo clinic prognosis model. Hepatology 1996; 24: 168A.
19. KILMURRY M R, HEATHCOTE E J, CAUCH-DUDEK K, et al. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology 1996; 23: 1148-53.
20. SAS Institute, Inc. SAS User's Guide. Volume 1. Cary NC: SAS Institute, Inc., 1989.
21. KAPLAN E L, MEIER P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
22. HARRINGTON D P, FLEMING T R. A class of rank test procedures for censored survival data. Biometrika 1982; 69: 553-66.
23. RYDNING A, SCHRUMPF E, ABDELNOOR M, et al. Factors of prognostic importance in primary biliary cirrhosis. Scand J Gastroenterol 1990; 25: 119-26.
24. GOUDIE B M, BURT A D, MACFARLANE G J, et al. Risk factors and prognosis in primary biliary cirrhosis. Am J Gastroenterol 1989; 84: 713-6.
25. ROLL J, BOYER J L, BARRY D, et al. The prognosis importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983; 308: 1-7.
26. COLOMBO C, CASTELLANI M R, BALISTRERI W F, et al. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992; 15: 677-84.
27. JAZRAWI R P, DE CAESTECKER J S, GOGGIN P M, el al. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994; 106: 134-42.
28. ++ mechanisms defective in cholestasis. J Clin Invest 1993; 92: 2984-93.